SafeBeat Rx—Moving ECG AI Beyond Diagnostics to Recommending Treatment
IEEE Pulse · 2026-03 · 17 (2) · 65-68
DOI: 10.1109/mpuls.2025.3618441 ↗Kurz gefasst
Fachartikel in der Zeitschrift IEEE Pulse, 2026-03. Verfasst von Rachita Navara und 2 weiteren Autor:innen. Hauptthemen laut MEDLINE: Electrocardiography, Signal Processing, Computer-Assisted, Long QT Syndrome. Die Arbeit nennt 18 Literaturangaben.
Abstract (Originalsprache)
Drug-induced QT prolongation is the leading cause of FDA nonapproval and a key safety concern for many medications, including cardiac drugs, antibiotics, psychotropic drugs, and oncology treatments. Conventional automated QT algorithms have shown variable reliability in recordings with abnormal or irregular morphology, with misclassification rates up to 75%. This article presents SafeBeat Rx, an AI-powered ECG platform that provides beat-by-beat ECG analysis, enabling full transparency and optional adjustment of measurements for each individual ECG heartbeat. Validated against expert cardiologist adjudication, SafeBeat addresses a critical gap in postdischarge cardiac surveillance and represents a novel approach to guideline-adherent pharmacological disease management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Zitieren
APA
Navara, R., Ferari, M., & McHugh, W. (2026). SafeBeat Rx—Moving ECG AI Beyond Diagnostics to Recommending Treatment. IEEE Pulse, 17(2), 65-68. https://doi.org/10.1109/mpuls.2025.3618441
Vancouver
Navara R, Ferari M, McHugh W. SafeBeat Rx—Moving ECG AI Beyond Diagnostics to Recommending Treatment. IEEE Pulse. 2026;17(2):65-68. doi:10.1109/mpuls.2025.3618441
BibTeX
@article{Navara2026,
author = {Navara, Rachita and Ferari, Margaret and McHugh, Walker},
title = {SafeBeat Rx—Moving ECG AI Beyond Diagnostics to Recommending Treatment},
journal = {IEEE Pulse},
year = {2026},
volume = {17},
number = {2},
pages = {65--68},
doi = {10.1109/mpuls.2025.3618441}
}
EUVIMED